Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

Sponsor: Seagen Inc.

Expanded Access

Sponsor score: 60

Inactive

ClinicalTrials ID:NCT06362590

This clinical trial program offers ladiratuzumab vedotin to eligible patients with advanced solid tumors. Participants must meet specific eligibility criteria to receive this drug intervention. The study aims to provide access to this treatment option for those who qualify under the SGNLVA-005 study parameters.

Patient Parameters

Parameter	Options

Program Overview

The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Get This Program In Your Inbox

You can sign up and apply your patients for this program.